Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 318, Issue 1, 2006, Pages 173-185

  Galici, Ruggero ^a,b   Jones, Carrie K ^a   Hemstapat, Kamondanai ^a   Nong, Yi ^a   Echemendia, Nicholas G ^a   Williams, Lilly C ^a   De Paulis, Tomas ^a   Conn, P Jeffrey ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,3 DICARBOXYCYCLOPROPYL)GLYCINE; 2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; AMPHETAMINE; BIPHENYLINDADONE A; GLUTAMIC ACID; INDANONE DERIVATIVE; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR AGONIST; NEUROLEPTIC AGENT; PHENCYCLIDINE; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN SLICE; CONTROLLED STUDY; DENTATE GYRUS; DRUG ANTAGONISM; DRUG EFFECT; DRUG INHIBITION; DRUG POTENTIATION; DRUG SYNTHESIS; HIPPOCAMPUS; HUMAN; HUMAN CELL; HYPERTHERMIA; IN VIVO STUDY; LOCOMOTION; MALE; MAZE TEST; NONHUMAN; PERFORANT NERVE TRACT; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; STRESS; SYNAPTIC POTENTIAL; TRANQUILIZING ACTIVITY;

ALLOSTERIC REGULATION; ANIMALS; ANTI-ANXIETY AGENTS; ANTIPSYCHOTIC AGENTS; BIPHENYL COMPOUNDS; CHO CELLS; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY POSTSYNAPTIC POTENTIALS; INDANS; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 33745227414     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.102046     Document Type: Article

References (39)

1. Bergink V, van Megen HJ, and Westenberg HG (2004) Glutamate and anxiety. Eur Neuropsychopharmacol 14:175-183.
2. Bonnefous C, Vernier JM, Hutchinson JH, Gardner MF, Cramer M, James JK, Rowe BA, Daggett LP, Schaffhauser H, and Kamenecka TM (2005) Biphenyl-indanones: allosteric potentiators of the metabotropic glutamate subtype 2 receptor. Bioorg Med Chem Lett 15:4354-4358.
3. s. J Pharmacol Exp Ther 294:539-547.
4. Cartmell J, Monn JA, and Schoepp DD (1999) The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J Pharmacol Exp Ther 291:161-170.
5. Cartmell J, Monn JA, and Schoepp DD (2000) The mGluR(2/3) receptor agonist LY379268 selectively blocks amphetamine ambulations and rearing. Eur J Pharmacol 400:221-224.
6. Conn PJ and Pin JP (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37:205-237.
7. Galici R, Echemendia NG, Rodriguez AL, and Conn PJ (2005) A selective allosteric potentiator of mGluR2 receptors has similar effects to an orthosteric mGluR2/3 agonist in mouse models predictive of antipsychotic activity. J Pharmacol Exp Ther 15:1181-1187.
8. o G proteins: evidence for agonist regulation of G protein selectivity. Br J Pharmacol 138:775-786.
9. Geyer MA and Ellenbroek B (2003) Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27:1071-1079.
10. Gillig JR, Heinz LJ, Kinnick MD, Lai Y-S, Morin JM, and Snyder NJ (2004) Novel melanin concentrating hormone receptor antagonists. WO052848, June 24.
11. Govek SP, Bonnefous C, Hutchinson JH, Kamenecka T, Acquisition J, Pracitto R, Zhao LX, Gardner MF, James JK, Daggett LP, et al. (2005) Benzazoles as allosteric potentiators of metabotropic glutamate receptor 2 (mGluR2): efficacy in an animal model for schizophrenia. Bioorg Med Chem Lett 15:3983-4154.
12. Grillon C, Cordova J, Levine LR, and Morgan CA 3rd (2003) Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans. Psychopharmacology 168:446-454.
13. Helton DR, Tizzano JP, Monn JA, Schoepp DD, and Kallman MJ (1998) Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J Pharmacol Exp Ther 284:651-660.
14. Jones CK, Eberle EL, Peters SC, Monn JA, and Shannon HE (2005) Analgesic effects of the selective group II (mGlu2/3) metabotropic glutamate receptor agonists LY379268 and LY389795 in persistent and inflammatory pain models after acute and repeated dosing. Neuropharmacology 49:206-218.
15. Johnson MP, Baez M, Jagdmann GE Jr, Britton TC, Large TH, Callagaro DO, Tizzano JP, Monn JA, and Schoepp DD (2003) Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-2-methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl) pyrid-3-ylmethylamine. J Med Chem 46:3189-3192.
16. Johnson MP, Barda D, Britton TC, Emkey R, Hornback WJ, Jagdmann GE, McKinzie DL, Nisenbaum ES, Tizzano JP, and Schoepp DD (2005) Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity and efficacy in preclinical anxiety and psychosis model(s). Psychopharmacology 179:271-283.
17. Kinney G, O'Brien JA, Lemaire W, Burno M, Bickel D, Clements MK, Wisnoski DD, Lindsley CW, Tiller PR, Smith S, et al. (2005) A novel selective allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5) has an antipsychotic profile in rat behavioral models. J Pharmacol Exp Ther 313:199-206.
18. Klein SI, Czkaj M, Gardner CJ, Guertin KR, Cheney DL, Spada AP, Bolton SA, Brown K, Colussi D, Heran CL, et al. (1998) Identification and initial structure-activity relationships of a novel class of nonpeptide inhibitors of blood coagulation factor Xa. J Med Chem 41:437-450.
19. Linden AM, Greene SJ, Bergeron M, and Schoepp DD (2004) Anxiolytic activity of the MGLU2/3 receptor agonist LY354740 on the elevated plus maze is associated with the suppression of stress-induced c-Fos in the hippocampus and increases in c-Fos induction in several other stress-sensitive brain regions. Neuropsychopharmacology 29:502-513.
20. Lister RG (1987) The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 92:180-185.
21. Macek TA, Schaffhauser H, and Conn PJ (1998) Protein kinase C and A3 adenosine receptor activation inhibit presynaptic metabotropic glutamate receptor (mGluR) function and uncouple mGluRs from GTP-binding proteins. J Neurosci 18:6138-6146.
22. Macek TA, Winder DG, Gereau RW 4th, Ladd CO, and Conn PJ (1996) Differential involvement of group II and group III mGluRs as autoreceptors at lateral and medial perforant path synapses. J Neurophysiol 76:3798-3806.
23. Marek GJ (2004) Metabotropic glutamate 2/3 receptors as drug targets. Curr Opin Pharmacol 4:18-22.
24. Marino MJ, Rouse ST, Levey AI, Potter LT, and Conn PJ (1998) Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-D-aspartate (NMDA) receptor currents in hippocampal pyramidal cells. Proc Natl Acad Sci USA 95:11465-11470.
25. Mitsukawa K, Yamamoto R, Ofner S, Nozulak J, Pescott O, Lukic S, Stoehr N, Mombereau C, Kuhn R, McAllister KH, et al. (2005) A selective metabotropic glutamate receptor 7 agonist: activation of receptor signaling via an allosteric site modulates stress parameters in vivo. Proc Natl Acad Sci USA 102:18712-18717.
26. Moghaddam B and Jackson ME (2003) Glutamatergic animal models of schizophrenia. Ann NY Acad Sci 1003:131-137.
27. Pinkerton AB, Cube RV, Hutchinson JH, James JK, Gardner MF, Rowe BA, Schaffhauser H, Rodriguez DE, Campbell UC, Daggett LP, et al. (2005) Allosteric potentiators of the metabotropic glutamate receptor 2 (mGluR2). Part 3: Identification and biological activity of indanone containing mGluR2 receptor potentiators. Bioorg Med Chem Lett 15:1565-1571.
28. Rodriguez D, Bonnefous C, Kamenecka T, Vernier J-M, Bristow L, and Campbell U (2004) Attenuation of ketamine-induced hyperactivity responses in rats following administration of a novel metabotropic glutamate receptor 2 selective positive modulator [abstract], in Proceedings of the Annual Meeting of the Society for Neuroscience; 2004 Oct 23-27; Abstract number 798.8, Dallas, TX. Society for Neuroscience, Washington, DC.
29. Rorick-Kehn LM, Perkins EJ, Knitowski KM, Hart JC, Johnson BG, Schoepp DD, and McKinzie DL (2006) Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344. J Pharmacol Exp Ther 316:905-913.
30. Schaffhauser H, Rowe BA, Morales S, Chavez-Noriega LE, Yin R, Jachec C, Rao SP, Bain G, Pinkerton AB, Vernier JM, et al. (2003) Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2. Mol Pharmacol 64:798-810.
31. Schoepp DD, Wright RA, Levine LR, Gaydos B, and Potter WZ (2003) LY354740, an mGluR2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress 6:189-197.
32. Spooren WP, Schoeffer P, Gasparini F, Kuhn R, and Gentsch C (2002) Pharmacological and endocrinological characterisation of stress-induced hyperthermia in singly housed mice using classical and candidate anxiolytics (LY314582, MPEP, and WKP608). Eur J Pharmacol 435:161-170.
33. Spalding TA, Trotter C, Skjaerbaek N, Messier TL, Currier EA, Burstein ES, Li D, Hacksell U, and Brann MR (2002) Discovery of an ectopic activation site on the M1 muscarinic receptor. Mol Pharmacol 61:1297-1302.
34. Sur C, Mallorga PJ, Wittmann M, Jacobson MA, Pascarella D, Williams JB, Brandish PE, Pettibone DJ, Scolnick EM, and Conn PJ (2003) N-Desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc Natl Acad Sci USA 100:13674-13679.
35. Swanson CJ, Bures M, Johnson MP, Linden AM, Monn JA, and Schoepp DD (2005) Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov 4:131-144.
36. Van der Heyden JA, Zethof TJ, and Olivier B (1997) Stress-induced hyperthermia in singly housed mice. Physiol Behav 62:463-470.
37. Walker DL and Davis M (2002) The role of amygdala glutamate receptors in fear learning, fear-potentiated startle and extinction. Pharmacol Biochem Behav 71:379-392.
38. Woltersdorf OW Jr., de Solms SJ, Schultz EM, and Cragoe EJ Jr. (1977) (Acylaryloxy) acetic acid diuetics. 1. (2-Akyl- and 2,2-dialkyl-1-oxo-5- indanyloxy) acetic acids. J Med Chem 20:1400-1408
39. Zhang Y, Rodriguez AL, and Conn PJ (2005) Allosteric potentiators of metabotropic pathways in cortical astrocytes. J Pharmacol Exp Ther 315:1212-1219.